Table: diabetes_ndcs_wac_increases_5_year_history , manufacturer_name like all*

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  *

year_str	oshpd_id	manufacturer_name	date_reported	ndc_number	drug_product_description	wac_effective_date	wac_increase_amount	wac_after_increase	patent_expiration_date	drug_source_type	unit_sales_volume_in_us	unit_sales_volume_non_public_indicator	cost_increase_factors	cost_increase_factors_non_public_indicator	change_improvement_description	change_improvement_non_public_indicator	acquisition_date	company_acquired_from	acquisition_price	acquisition_price_non_public_indicator	acquisition_price_comment	wac_at_acquisition	wac_year_prior_to_acquisition	year_drug_introduced_to_market	wac_at_intro_to_market	supporting_documents	general_comments
2019	Rx0000033	Novo	03/31/2019	00169406012	Victoza? 6mg/mL 2x3mL	01/08/2019	34.26	614.52	08/22/2022	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	NNI holds a number of patents related to Victoza. We've included the expiration date for Patent #6268343 which is the compound patent for Victoza. NNI has applied for pediatric exclusivity. If granted, this will add 6 months to all Orange Book exclusivities. NNI is the original manufacturer of this product (Victoza) and did not acquire the product from a different company.
2019	Rx0000033	Novo	03/31/2019	169406013	Victoza? 6mg/mL 3x3mL	01/08/2019	51.39	921.78	08/22/2022	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	NNI holds a number of patents related to Victoza. We've included the expiration date for Patent #6268343 which is the compound patent for Victoza. NNI has applied for pediatric exclusivity. If granted, this will add 6 months to all Orange Book exclusivities. NNI is the original manufacturer of this product (Victoza) and did not acquire the product from a different company.
2019	Rx0000015	AstraZeneca	03/31/2019	00310620530	Farxiga 5mg	01/01/2019	27.87	492.41	10/04/2025	Single Source Drug	599751771	None	AstraZeneca makes decisions on price revisions annually based on market conditions, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients. When making pricing decisions AstraZeneca takes the following actions: - We take into account not only the budget impact to payers but also consider patient out of pocket costs to ensure that our treatments reach the patients who need them. - We seek feedback from payers and providers through meetings, advisory boards, and third party research. - We price responsibly and in line with current treatment costs where treatment options exist. - We consider factors such as Annual CPI-U rates and increases in manufacturing and transportation costs. - We reinvest into R&D to identify future medicines to improve the lives of patients.	None	AstraZeneca is a science-led biopharmaceutical business, and our innovative medicines are used by millions of patients worldwide. Patients and science are at the heart of everything we do, and we put careful consideration into determining the value and ultimately the cost of our medicines. Many factors go into these decisions such as the benefits our medicines provide and their potential to reduce healthcare spending on other costlier medical procedures. Equally important, these decisions enable us to invest in discovering and developing future innovative medicines where new treatments are needed.	None	02/01/2014	Bristol-Myers Squibb	2700000000	None	AstraZeneca paid Bristol-Myers Squibb $2.7 billion of initial consideration. AstraZeneca has also agreed to pay up to $1.4 billion in regulatory, launch and sales payments, and various sales-related royalty payments up until 2025, $600 million of which relates to the approval of Farxiga in the US. In addition, AstraZeneca may make payments of up to $225 million when certain assets are subsequently transferred.	289.20	None	2014	289.20	None	None
2019	Rx0000015	AstraZeneca	03/31/2019	00310621030	Farxiga 10mg	01/01/2019	27.87	492.41	10/04/2025	Single Source Drug	1289346480	None	AstraZeneca makes decisions on price revisions annually based on market conditions, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients. When making pricing decisions AstraZeneca takes the following actions: - We take into account not only the budget impact to payers but also consider patient out of pocket costs to ensure that our treatments reach the patients who need them. - We seek feedback from payers and providers through meetings, advisory boards, and third party research. - We price responsibly and in line with current treatment costs where treatment options exist. - We consider factors such as Annual CPI-U rates and increases in manufacturing and transportation costs. - We reinvest into R&D to identify future medicines to improve the lives of patients.	None	AstraZeneca is a science-led biopharmaceutical business, and our innovative medicines are used by millions of patients worldwide. Patients and science are at the heart of everything we do, and we put careful consideration into determining the value and ultimately the cost of our medicines. Many factors go into these decisions such as the benefits our medicines provide and their potential to reduce healthcare spending on other costlier medical procedures. Equally important, these decisions enable us to invest in discovering and developing future innovative medicines where new treatments are needed.	None	02/01/2014	Bristol-Myers Squibb	2700000000	None	AstraZeneca paid Bristol-Myers Squibb $2.7 billion of initial consideration. AstraZeneca has also agreed to pay up to $1.4 billion in regulatory, launch and sales payments, and various sales-related royalty payments up until 2025, $600 million of which relates to the approval of Farxiga in the US. In addition, AstraZeneca may make payments of up to $225 million when certain assets are subsequently transferred.	289.20	None	2014	289.20	None	None
2019	Rx0000015	AstraZeneca	03/31/2019	00310625030	Xigduo XR 5-500mg	01/01/2019	27.87	492.41	10/04/2025	Single Source Drug	22269231	None	AstraZeneca makes decisions on price revisions annually based on market conditions, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients. When making pricing decisions AstraZeneca takes the following actions: - We take into account not only the budget impact to payers but also consider patient out of pocket costs to ensure that our treatments reach the patients who need them. - We seek feedback from payers and providers through meetings, advisory boards, and third party research. - We price responsibly and in line with current treatment costs where treatment options exist. - We consider factors such as Annual CPI-U rates and increases in manufacturing and transportation costs. - We reinvest into R&D to identify future medicines to improve the lives of patients.	None	AstraZeneca is a science-led biopharmaceutical business, and our innovative medicines are used by millions of patients worldwide. Patients and science are at the heart of everything we do, and we put careful consideration into determining the value and ultimately the cost of our medicines. Many factors go into these decisions such as the benefits our medicines provide and their potential to reduce healthcare spending on other costlier medical procedures. Equally important, these decisions enable us to invest in discovering and developing future innovative medicines where new treatments are needed.	None	None	None	None	None	None	None	None	None	None	None	AstraZeneca developed this NDC, it was not acquired within the last five years.
2019	Rx0000015	AstraZeneca	03/31/2019	00310626060	Xigduo XR 5-1000mg	01/01/2019	27.87	492.41	10/04/2025	Single Source Drug	212483946	None	AstraZeneca makes decisions on price revisions annually based on market conditions, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients. When making pricing decisions AstraZeneca takes the following actions: - We take into account not only the budget impact to payers but also consider patient out of pocket costs to ensure that our treatments reach the patients who need them. - We seek feedback from payers and providers through meetings, advisory boards, and third party research. - We price responsibly and in line with current treatment costs where treatment options exist. - We consider factors such as Annual CPI-U rates and increases in manufacturing and transportation costs. - We reinvest into R&D to identify future medicines to improve the lives of patients.	None	AstraZeneca is a science-led biopharmaceutical business, and our innovative medicines are used by millions of patients worldwide. Patients and science are at the heart of everything we do, and we put careful consideration into determining the value and ultimately the cost of our medicines. Many factors go into these decisions such as the benefits our medicines provide and their potential to reduce healthcare spending on other costlier medical procedures. Equally important, these decisions enable us to invest in discovering and developing future innovative medicines where new treatments are needed.	None	None	None	None	None	None	None	None	None	None	None	AstraZeneca developed this NDC, it was not acquired within the last five years.
2019	Rx0000015	AstraZeneca	03/31/2019	00310627030	Xigduo XR 10-500mg	01/01/2019	27.87	492.41	10/04/2025	Single Source Drug	13322599	None	AstraZeneca makes decisions on price revisions annually based on market conditions, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients. When making pricing decisions AstraZeneca takes the following actions: - We take into account not only the budget impact to payers but also consider patient out of pocket costs to ensure that our treatments reach the patients who need them. - We seek feedback from payers and providers through meetings, advisory boards, and third party research. - We price responsibly and in line with current treatment costs where treatment options exist. - We consider factors such as Annual CPI-U rates and increases in manufacturing and transportation costs. - We reinvest into R&D to identify future medicines to improve the lives of patients.	None	AstraZeneca is a science-led biopharmaceutical business, and our innovative medicines are used by millions of patients worldwide. Patients and science are at the heart of everything we do, and we put careful consideration into determining the value and ultimately the cost of our medicines. Many factors go into these decisions such as the benefits our medicines provide and their potential to reduce healthcare spending on other costlier medical procedures. Equally important, these decisions enable us to invest in discovering and developing future innovative medicines where new treatments are needed.	None	None	None	None	None	None	None	None	None	None	None	AstraZeneca developed this NDC, it was not acquired within the last five years.
2019	Rx0000015	AstraZeneca	03/31/2019	00310628030	Xigduo XR 10-1000mg	01/01/2019	27.87	492.41	10/04/2025	Single Source Drug	129626100	None	AstraZeneca makes decisions on price revisions annually based on market conditions, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients. When making pricing decisions AstraZeneca takes the following actions: - We take into account not only the budget impact to payers but also consider patient out of pocket costs to ensure that our treatments reach the patients who need them. - We seek feedback from payers and providers through meetings, advisory boards, and third party research. - We price responsibly and in line with current treatment costs where treatment options exist. - We consider factors such as Annual CPI-U rates and increases in manufacturing and transportation costs. - We reinvest into R&D to identify future medicines to improve the lives of patients.	None	AstraZeneca is a science-led biopharmaceutical business, and our innovative medicines are used by millions of patients worldwide. Patients and science are at the heart of everything we do, and we put careful consideration into determining the value and ultimately the cost of our medicines. Many factors go into these decisions such as the benefits our medicines provide and their potential to reduce healthcare spending on other costlier medical procedures. Equally important, these decisions enable us to invest in discovering and developing future innovative medicines where new treatments are needed.	None	None	None	None	None	None	None	None	None	None	None	AstraZeneca developed this NDC, it was not acquired within the last five years.
2019	Rx0000038	Boehringer Ingelheim	03/31/2019	00597014030	TRADJENTA 5 MG TABLET	01/01/2019	24.69	436.17	03/05/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=228	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2019	Rx0000038	Boehringer Ingelheim	03/31/2019	00597014061	TRADJENTA 5 MG TABLET	01/01/2019	82.30	1453.90	03/05/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=229	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2019	Rx0000038	Boehringer Ingelheim	03/31/2019	00597014090	TRADJENTA 5 MG TABLET	01/01/2019	74.07	1308.51	03/05/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=230	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2019	Rx0000038	Boehringer Ingelheim	03/31/2019	00597014618	JENTADUETO 2.5 MG-500 MG TAB	01/01/2019	74.07	1308.51	06/04/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=169	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2019	Rx0000038	Boehringer Ingelheim	03/31/2019	00597014660	JENTADUETO 2.5 MG-500 MG TAB	01/01/2019	24.69	436.17	06/04/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=170	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2019	Rx0000038	Boehringer Ingelheim	03/31/2019	00597014718	JENTADUETO 2.5 MG-850 MG TAB	01/01/2019	74.07	1308.51	06/04/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=171	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2019	Rx0000038	Boehringer Ingelheim	03/31/2019	00597014760	JENTADUETO 2.5 MG-850 MG TAB	01/01/2019	24.69	436.17	06/04/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=172	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2019	Rx0000038	Boehringer Ingelheim	03/31/2019	00597014818	JENTADUETO 2.5 MG-1,000 MG TAB	01/01/2019	74.07	1308.51	06/04/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=173	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2019	Rx0000038	Boehringer Ingelheim	03/31/2019	00597014860	JENTADUETO 2.5 MG-1,000 MG TAB	01/01/2019	24.69	436.17	06/04/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=174	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2019	Rx0000038	Boehringer Ingelheim	03/31/2019	00597015230	JARDIANCE 10 MG TABLET	01/01/2019	27.90	492.85	06/11/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=163	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2019	Rx0000038	Boehringer Ingelheim	03/31/2019	00597015237	JARDIANCE 10 MG TABLET	01/01/2019	27.90	492.85	06/11/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=164	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2019	Rx0000038	Boehringer Ingelheim	03/31/2019	00597015290	JARDIANCE 10 MG TABLET	01/01/2019	83.69	1478.54	06/11/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=165	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2019	Rx0000038	Boehringer Ingelheim	03/31/2019	00597015330	JARDIANCE 25 MG TABLET	01/01/2019	27.90	492.85	06/11/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=166	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2019	Rx0000038	Boehringer Ingelheim	03/31/2019	00597015337	JARDIANCE 25 MG TABLET	01/01/2019	27.90	492.85	06/11/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=167	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2019	Rx0000038	Boehringer Ingelheim	03/31/2019	00597015390	JARDIANCE 25 MG TABLET	01/01/2019	83.69	1478.54	06/11/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=168	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2019	Rx0000038	Boehringer Ingelheim	03/31/2019	00597015918	SYNJARDY 5-500 MG TABLET	01/01/2019	83.69	1478.54	04/15/2027	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=220	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2019	Rx0000038	Boehringer Ingelheim	03/31/2019	00597015960	SYNJARDY 5-500 MG TABLET	01/01/2019	27.90	492.85	04/15/2027	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=221	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2019	Rx0000038	Boehringer Ingelheim	03/31/2019	00597016818	SYNJARDY 12.5-1,000 MG TABLET	01/01/2019	83.69	1478.54	04/15/2027	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=222	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2019	Rx0000038	Boehringer Ingelheim	03/31/2019	00597016860	SYNJARDY 12.5-1,000 MG TABLET	01/01/2019	27.90	492.85	04/15/2027	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=223	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2019	Rx0000038	Boehringer Ingelheim	03/31/2019	00597017518	SYNJARDY 5-1,000 MG TABLET	01/01/2019	83.69	1478.54	04/15/2027	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=224	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2019	Rx0000038	Boehringer Ingelheim	03/31/2019	00597017560	SYNJARDY 5-1,000 MG TABLET	01/01/2019	27.90	492.85	04/15/2027	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=225	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2019	Rx0000038	Boehringer Ingelheim	03/31/2019	00597018018	SYNJARDY 12.5-500 MG TABLET	01/01/2019	83.69	1478.54	04/15/2027	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=226	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2019	Rx0000038	Boehringer Ingelheim	03/31/2019	00597018060	SYNJARDY 12.5-500 MG TABLET	01/01/2019	27.90	492.85	04/15/2027	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=227	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2019	Rx0000038	Boehringer Ingelheim	03/31/2019	00597027073	JENTADUETO XR 2.5 MG-1,000 MG	01/01/2019	24.69	436.17	03/06/2033	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=175	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2019	Rx0000038	Boehringer Ingelheim	03/31/2019	00597027094	JENTADUETO XR 2.5 MG-1,000 MG	01/01/2019	74.07	1308.51	03/06/2033	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=176	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2019	Rx0000038	Boehringer Ingelheim	03/31/2019	00597027533	JENTADUETO XR 5 MG-1,000 MG TB	01/01/2019	24.69	436.17	03/06/2033	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=177	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2019	Rx0000038	Boehringer Ingelheim	03/31/2019	00597027581	JENTADUETO XR 5 MG-1,000 MG TB	01/01/2019	74.07	1308.51	03/06/2033	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=178	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2019	Rx0000122	Amneal Pharmaceuticals	03/31/2019	60846088201	Prandin® (repaglinide tablets) 1mg 100 Tabs	01/04/2019	71.40	792.64	None	Non-innovator Multiple Source Drug	5667	None	Manufacturing costs and market conditions require increase to remain on market	None	None	1	05/07/2018	Gemini Laboratories, LLC	None	None	Amneal does not have the ability to separate the portion of the total acquisition price allocated to the individual drug products. Total amount was 117000000	656.26	625.61	2013	339.25	None	Column 12 Blank - No change to the product
2019	Rx0000122	Amneal Pharmaceuticals	03/31/2019	60846088401	Prandin® (repaglinide tablets) 2mg 100 Tab	01/04/2019	71.40	792.64	None	Non-innovator Multiple Source Drug	9733	None	Manufacturing costs and market conditions require increase to remain on market	None	None	1	05/07/2018	Gemini Laboratories, LLC	None	None	Amneal does not have the ability to separate the portion of the total acquisition price allocated to the individual drug products. Total amount was 117000000	656.26	625.61	2013	339.25	None	Column 12 Blank - No change to the product
2019	Rx0000092	Santarus, Inc.	03/31/2019	68012025820	CYCLOSET® (bromocriptine mesytate tablets) 0.8 mg tablets	01/18/2019	47.48	838.74	04/30/2032	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.
2019	Rx0000231	American Health Packaging	12/31/2019	68084011201	Glipizide ER Tablet 10mg 100UD	12/05/2019	15.50	88.44	None	Non-innovator Multiple Source Drug	2238	None	Market Conditions	None	No change or improvement in the drug product	None	None	None	None	None	None	None	None	None	None	None	The acquisition fields do not need to be filled out because the drug was not acquired within the previous 5 years. All the fields that are left blank are due to "Not Applicable".
2019	Rx0000154	Corcept Therapeutics Incorporated	09/30/2019	76346007301	Korlym (mifepristone) 300mg Tablets 28-ct Bottles	08/01/2019	1148.00	13972.00	08/22/2038	Single Source Drug	None	1	Corcept is committed to discovering, developing and making available to patients and physicians medicines that treat serious disorders for which there are few – or no – good treatment options. In setting Korlym’s price, we weigh (i) the increased cost of administrative and commercial activities, (ii) the increased cost of discovering and developing innovative new drug candidates and (iii) our commitment that no patient be denied Korlym for financial reasons.	None	N/A	None	None	None	None	None	None	None	None	None	None	None	WAC is reported at the package level. The information provided herein is provided to the best of our knowledge as of submission and based on our interpretation of applicable statutory and regulatory provisions. Information designated as confidential has been designated as such based on our understanding and belief that the subject information is non-public. Our provision of information shall not be interpreted as a waiver of any of our rights available under state, federal, or other applicable law with respect to the information contained herein or with respect to California SB 17, all of which we expressly reserve. Patent expiration dates do not reflect any pending patent applications, future filed patent applications, patent term extensions, data exclusivity (including orphan drug, pediatric, or other exclusivity), or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. The drug was developed by Corcept.
2019	Rx0000154	Corcept Therapeutics Incorporated	09/30/2019	76346007302	Korlym (mifepristone) 300mg Tablets 280-ct Bottles	08/01/2019	11480.00	139720.00	08/22/2038	Single Source Drug	None	1	Corcept is committed to discovering, developing and making available to patients and physicians medicines that treat serious disorders for which there are few – or no – good treatment options. In setting Korlym’s price, we weigh (i) the increased cost of administrative and commercial activities, (ii) the increased cost of discovering and developing innovative new drug candidates and (iii) our commitment that no patient be denied Korlym for financial reasons.	None	N/A	None	None	None	None	None	None	None	None	None	None	None	WAC is reported at the package level. The information provided herein is provided to the best of our knowledge as of submission and based on our interpretation of applicable statutory and regulatory provisions. Information designated as confidential has been designated as such based on our understanding and belief that the subject information is non-public. Our provision of information shall not be interpreted as a waiver of any of our rights available under state, federal, or other applicable law with respect to the information contained herein or with respect to California SB 17, all of which we expressly reserve. Patent expiration dates do not reflect any pending patent applications, future filed patent applications, patent term extensions, data exclusivity (including orphan drug, pediatric, or other exclusivity), or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. The drug was developed by Corcept.
2020	Rx0000114	Eli Lilly and Company	03/31/2020	00002143380	TRULICITY™ 0.75 mg/0.5 mL carton of 4 single-dose pens	01/31/2020	37.90	797.30	12/27/2027	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All information is provided by Eli Lilly and Company ("Lilly") to the best of our knowledge at the time of submission. Lilly provides this report consistent with its understanding and interpretation of California Health and Safety Code Chapter 9 §127675-127686 and its related provisions. In providing this report, Lilly does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California Health and Safety Code Chapter 9 §127675-127686 as it may relate to Lilly or any of its affiliates now or in the future. Lilly, on behalf of itself and affiliates, expressly reserves all such rights. The reported patent expiration information relates to only one or more compound patents covering TRULICITY™ and does not reflect pending possible patent extensions or patents, including pending patent applications, that may cover other aspects of TRULICITY™. Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Lilly believes is otherwise in the public domain or publicly available. This product was not acquired within the last 5 years, therefore columns 14-21 are intentionally left blank.
2020	Rx0000114	Eli Lilly and Company	03/31/2020	00002143480	TRULICITY™ 1.5 mg /0.5mL carton of 4 single-dose pens	01/31/2020	37.90	797.30	12/27/2027	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	All information is provided by Eli Lilly and Company ("Lilly") to the best of our knowledge at the time of submission. Lilly provides this report consistent with its understanding and interpretation of California Health and Safety Code Chapter 9 §127675-127686 and its related provisions. In providing this report, Lilly does not waive any rights that it may have at law or in equity with respect to the applicability, interpretation, or application of California Health and Safety Code Chapter 9 §127675-127686 as it may relate to Lilly or any of its affiliates now or in the future. Lilly, on behalf of itself and affiliates, expressly reserves all such rights. The reported patent expiration information relates to only one or more compound patents covering TRULICITY™ and does not reflect pending possible patent extensions or patents, including pending patent applications, that may cover other aspects of TRULICITY™. Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Lilly believes is otherwise in the public domain or publicly available. This product was not acquired within the last 5 years, therefore columns 14-21 are intentionally left blank.
2020	Rx0000138	Merck & Co., Inc.	03/31/2020	00006007861	JANUMET XR 50 mg-500 mg Tablets 60	01/03/2020	22.20	473.40	11/24/2026	Single Source Drug	None	1	Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding: •capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers. •investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people. Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase.	None	There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development.	None	None	None	None	None	None	None	None	None	None	None	Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677), the information provided is limited to information Merck believes is in the public domain, unless otherwise indicated; (2) the columns requiring information relating to product acquisition are left blank because the product was not acquired by Merck or not acquired by Merck in the previous five years.
2020	Rx0000138	Merck & Co., Inc.	03/31/2020	00006007862	JANUMET XR 50 mg-500 mg Tablets 180	01/03/2020	66.60	1420.20	11/24/2026	Single Source Drug	None	1	Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding: •capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers. •investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people. Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase.	None	There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development.	None	None	None	None	None	None	None	None	None	None	None	Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677), the information provided is limited to information Merck believes is in the public domain, unless otherwise indicated; (2 )the columns requiring information relating to product acquisition are left blank because the product was not acquired by Merck or not acquired by Merck in the previous five years.
2020	Rx0000138	Merck & Co., Inc.	03/31/2020	00006007882	JANUMET XR 50 mg-500 mg Tablets 1000	01/03/2020	370.00	7890.00	11/24/2026	Single Source Drug	None	1	Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding: •capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers. •investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people. Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase.	None	There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development.	None	None	None	None	None	None	None	None	None	None	None	Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677), the information provided is limited to information Merck believes is in the public domain, unless otherwise indicated; (2) the columns requiring information relating to product acquisition are left blank because the product was not acquired by Merck or not acquired by Merck in the previous five years.
2020	Rx0000138	Merck & Co., Inc.	03/31/2020	00006008061	JANUMET XR 50 mg-1000 mg Tablets 60	01/03/2020	22.20	473.40	11/24/2026	Single Source Drug	None	1	Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding: •capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers. •investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people. Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase.	None	There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development.	None	None	None	None	None	None	None	None	None	None	None	Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677), the information provided is limited to information Merck believes is in the public domain, unless otherwise indicated; (2) the columns requiring information relating to product acquisition are left blank because the product was not acquired by Merck or not acquired by Merck in the previous five years.
2020	Rx0000138	Merck & Co., Inc.	03/31/2020	00006008062	JANUMET XR 50 mg-1000 mg Tablets 180	01/03/2020	66.60	1420.20	11/24/2026	Single Source Drug	None	1	Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding: •capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers. •investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people. Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase.	None	There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development.	None	None	None	None	None	None	None	None	None	None	None	Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677), the information provided is limited to information Merck believes is in the public domain, unless otherwise indicated; (2) the columns requiring information relating to product acquisition are left blank because the product was not acquired by Merck or not acquired by Merck in the previous five years.
2020	Rx0000138	Merck & Co., Inc.	03/31/2020	00006008082	JANUMET XR 50 mg-1000 mg Tablets 1000	01/03/2020	370.00	7890.00	11/24/2026	Single Source Drug	None	1	Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding: •capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers. •investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people. Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase.	None	There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development.	None	None	None	None	None	None	None	None	None	None	None	Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677), the information provided is limited to information Merck believes is in the public domain, unless otherwise indicated; (2) the columns requiring information relating to product acquisition are left blank because the product was not acquired by Merck or not acquired by Merck in the previous five years.
2020	Rx0000138	Merck & Co., Inc.	03/31/2020	00006008131	JANUMET XR 100 mg-1000 mg Tablets 30	01/03/2020	22.20	473.40	11/24/2026	Single Source Drug	None	1	Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding: •capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers. •investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people. Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase.	None	There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development.	None	None	None	None	None	None	None	None	None	None	None	Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677), the information provided is limited to information Merck believes is in the public domain, unless otherwise indicated; (2) the columns requiring information relating to product acquisition are left blank because the product was not acquired by Merck or not acquired by Merck in the previous five years.
2020	Rx0000138	Merck & Co., Inc.	03/31/2020	00006008154	JANUMET XR 100 mg-1000 mg Tablets 90	01/03/2020	66.60	1420.20	11/24/2026	Single Source Drug	None	1	Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding: •capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers. •investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people. Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase.	None	There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development.	None	None	None	None	None	None	None	None	None	None	None	Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677), the information provided is limited to information Merck believes is in the public domain, unless otherwise indicated; (2) the columns requiring information relating to product acquisition are left blank because the product was not acquired by Merck or not acquired by Merck in the previous five years.
2020	Rx0000138	Merck & Co., Inc.	03/31/2020	00006008182	JANUMET XR 100 mg-1000 mg Tablets 1000	01/03/2020	740.00	15780.00	11/24/2026	Single Source Drug	None	1	Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding: •capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers. •investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people. Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase.	None	There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development.	None	None	None	None	None	None	None	None	None	None	None	Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677), the information provided is limited to information Merck believes is in the public domain, unless otherwise indicated; (2) the columns requiring information relating to product acquisition are left blank because the product was not acquired by Merck or not acquired by Merck in the previous five years.
2020	Rx0000138	Merck & Co., Inc.	03/31/2020	00006011228	JANUVIA 50 mg Tablets 100	01/03/2020	74.00	1578.00	11/24/2026	Single Source Drug	None	1	Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding: •capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers. •investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people. Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase.	None	There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development.	None	None	None	None	None	None	None	None	None	None	None	Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677), the information provided is limited to information Merck believes is in the public domain, unless otherwise indicated; (2) the columns requiring information relating to product acquisition are left blank for products that were not acquired by Merck in the previous five years.
2020	Rx0000138	Merck & Co., Inc.	03/31/2020	00006011231	JANUVIA 50 mg Tablets 30	01/03/2020	22.20	473.40	11/24/2026	Single Source Drug	None	1	Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding: •capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers. •investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people. Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase.	None	There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development.	None	None	None	None	None	None	None	None	None	None	None	Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677), the information provided is limited to information Merck believes is in the public domain, unless otherwise indicated; (2) the columns requiring information relating to product acquisition are left blank for products that were not acquired by Merck in the previous five years.
2020	Rx0000138	Merck & Co., Inc.	03/31/2020	00006011254	JANUVIA 50 mg Tablets 90	01/03/2020	66.60	1420.20	11/24/2026	Single Source Drug	None	1	Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding: •capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers. •investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people. Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase.	None	There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development.	None	None	None	None	None	None	None	None	None	None	None	Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677), the information provided is limited to information Merck believes is in the public domain, unless otherwise indicated; (2) the columns requiring information relating to product acquisition are left blank for products that were not acquired by Merck in the previous five years.
2020	Rx0000138	Merck & Co., Inc.	03/31/2020	00006022128	JANUVIA 25 mg Tablets 100	01/03/2020	74.00	1578.00	11/24/2026	Single Source Drug	None	1	Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding: •capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers. •investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people. Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase.	None	There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development.	None	None	None	None	None	None	None	None	None	None	None	Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677), the information provided is limited to information Merck believes is in the public domain, unless otherwise indicated; (2) the columns requiring information relating to product acquisition are left blank for products that were not acquired by Merck in the previous five years.
2020	Rx0000138	Merck & Co., Inc.	03/31/2020	00006022131	JANUVIA 25 mg Tablets 30	01/03/2020	22.20	473.40	11/24/2026	Single Source Drug	None	1	Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding: •capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers. •investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people. Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase.	None	There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development.	None	None	None	None	None	None	None	None	None	None	None	Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677), the information provided is limited to information Merck believes is in the public domain, unless otherwise indicated; (2) the columns requiring information relating to product acquisition are left blank for products that were not acquired by Merck in the previous five years.
2020	Rx0000138	Merck & Co., Inc.	03/31/2020	00006022154	JANUVIA 25 mg Tablets 90	01/03/2020	66.60	1420.20	11/24/2026	Single Source Drug	None	1	Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding: •capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers. •investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people. Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase.	None	There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development.	None	None	None	None	None	None	None	None	None	None	None	Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677), the information provided is limited to information Merck believes is in the public domain, unless otherwise indicated; (2) the columns requiring information relating to product acquisition are left blank for products that were not acquired by Merck in the previous five years.
2020	Rx0000138	Merck & Co., Inc.	03/31/2020	00006027728	JANUVIA 100 mg Tablets 100	01/03/2020	74.00	1578.00	11/24/2026	Single Source Drug	None	1	Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding: •capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers. •investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people. Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase.	None	There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development.	None	None	None	None	None	None	None	None	None	None	None	Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677), the information provided is limited to information Merck believes is in the public domain, unless otherwise indicated; (2) the columns requiring information relating to product acquisition are left blank because the product was not acquired by Merck or not acquired by Merck in the previous five years.
2020	Rx0000138	Merck & Co., Inc.	03/31/2020	00006027731	JANUVIA 100 mg Tablets 30	01/03/2020	22.20	473.40	11/24/2026	Single Source Drug	None	1	Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding: •capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers. •investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people. Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase.	None	There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development.	None	None	None	None	None	None	None	None	None	None	None	Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677), the information provided is limited to information Merck believes is in the public domain, unless otherwise indicated; (2) the columns requiring information relating to product acquisition are left blank for products that were not acquired by Merck in the previous five years.
2020	Rx0000138	Merck & Co., Inc.	03/31/2020	00006027754	JANUVIA 100 mg Tablets 90	01/03/2020	66.60	1420.20	11/24/2026	Single Source Drug	None	1	Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding: •capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers. •investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people. Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase.	None	There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development.	None	None	None	None	None	None	None	None	None	None	None	Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677), the information provided is limited to information Merck believes is in the public domain, unless otherwise indicated; (2) the columns requiring information relating to product acquisition are left blank for products that were not acquired by Merck in the previous five years.
2020	Rx0000138	Merck & Co., Inc.	03/31/2020	00006027782	JANUVIA 100 mg Tablets 1000	01/03/2020	740.00	15780.00	11/24/2026	Single Source Drug	None	1	Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding: •capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers. •investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people. Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase.	None	There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development.	None	None	None	None	None	None	None	None	None	None	None	Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677), the information provided is limited to information Merck believes is in the public domain, unless otherwise indicated; (2) the columns requiring information relating to product acquisition are left blank because the product was not acquired by Merck or not acquired by Merck in the previous five years.
2020	Rx0000138	Merck & Co., Inc.	03/31/2020	00006057561	JANUMET 50 mg-500 mg Tablets 60	01/03/2020	22.20	473.40	07/21/2028	Single Source Drug	None	1	Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding: •capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers. •investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people. Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase.	None	There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development.	None	None	None	None	None	None	None	None	None	None	None	Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677), the information provided is limited to information Merck believes is in the public domain, unless otherwise indicated; (2) the columns requiring information relating to product acquisition are left blank because the product was not acquired by Merck or not acquired by Merck in the previous five years.
2020	Rx0000138	Merck & Co., Inc.	03/31/2020	00006057562	JANUMET 50 mg-500 mg Tablets 180	01/03/2020	66.60	1420.20	07/21/2028	Single Source Drug	None	1	Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding: •capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers. •investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people. Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase.	None	There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development.	None	None	None	None	None	None	None	None	None	None	None	Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677), the information provided is limited to information Merck believes is in the public domain, unless otherwise indicated; (2) the columns requiring information relating to product acquisition are left blank because the product was not acquired by Merck or not acquired by Merck in the previous five years.
2020	Rx0000138	Merck & Co., Inc.	03/31/2020	00006057582	JANUMET 50 mg-500 mg Tablets 1000	01/03/2020	370.00	7890.00	07/21/2028	Single Source Drug	None	1	Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding: •capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers. •investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people. Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase.	None	There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development.	None	None	None	None	None	None	None	None	None	None	None	Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677), the information provided is limited to information Merck believes is in the public domain, unless otherwise indicated; (2) the columns requiring information relating to product acquisition are left blank because the product was not acquired by Merck or not acquired by Merck in the previous five years.
2020	Rx0000138	Merck & Co., Inc.	03/31/2020	00006057761	JANUMET 50 mg-1000 mg Tablets 60	01/03/2020	22.20	473.40	07/21/2028	Single Source Drug	None	1	Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding: •capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers. •investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people. Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase.	None	There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development.	None	None	None	None	None	None	None	None	None	None	None	Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677), the information provided is limited to information Merck believes is in the public domain, unless otherwise indicated; (2) the columns requiring information relating to product acquisition are left blank because the product was not acquired by Merck or not acquired by Merck in the previous five years.
2020	Rx0000138	Merck & Co., Inc.	03/31/2020	00006057762	JANUMET 50 mg-1000 mg Tablets 180	01/03/2020	66.60	1420.20	07/21/2028	Single Source Drug	None	1	Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding: •capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers. •investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people. Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase.	None	There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development.	None	None	None	None	None	None	None	None	None	None	None	Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677), the information provided is limited to information Merck believes is in the public domain, unless otherwise indicated; (2) the columns requiring information relating to product acquisition are left blank because the product was not acquired by Merck or not acquired by Merck in the previous five years.
2020	Rx0000138	Merck & Co., Inc.	03/31/2020	00006057782	JANUMET 50 mg-1000 mg Tablets 1000	01/03/2020	370.00	7890.00	07/21/2028	Single Source Drug	None	1	Merck periodically increases the list price of our medicines, including those reported in Merck’s annual price increase report, to recognize the value they provide to patients, recoup the cost of inflation, adapt to changing market conditions and competitive considerations, and most importantly, to help fund research and development and bring forward new medicines. In addition to reflecting the steadily escalating cost of doing business, our price actions are critical to funding: •capital investments in the U.S. of more than $5 billion in the last five years, with planned investment of $9 billion more in the U.S. over the next few years to increase manufacturing capacity and to open two new discovery research centers. •investments in research and development that last year alone totaled nearly $10 billion ($70 billion since 2010), focused on cancer and infectious diseases, as well as other major health challenges that affect large numbers of people. Merck does not maintain records that reflect how these factors were applied in the context of any particular product or price increase.	None	There is no specific change or improvement to the listed product that would “necessitate” a change in the product’s Wholesale Acquisition Cost. Merck's goal is to set prices at levels that allow patients to access medicines prescribed for them, while allowing for sustained funding of research and development.	None	None	None	None	None	None	None	None	None	None	None	Merck’s submission to OSHPD is subject to the following assumptions and context: (1) pursuant to California Senate Bill 17 and the laws it implements (including Cal. Health & Safety Code § 127677), the information provided is limited to information Merck believes is in the public domain, unless otherwise indicated; (2) the columns requiring information relating to product acquisition are left blank because the product was not acquired by Merck or not acquired by Merck in the previous five years.
2020	Rx0000033	Novo	03/31/2020	00169406012	Victoza 6mg/mL 2x3mL Prefilled Pens	01/10/2020	30.72	645.24	07/09/2037	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	NNI holds a number of patents related to Victoza. We've included the expiration date for Patent #9968659 which is the patent with the latest expiry date in the FDA Orange Book. NNI is the original manufacturer of Victoza and did not acquire the product from a different company.
2020	Rx0000033	Novo	03/31/2020	00169406013	Victoza 6mg/mL 3x3mL Prefilled Pens	01/10/2020	46.08	967.86	07/09/2037	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	NNI holds a number of patents related to Victoza. We've included the expiration date for Patent #9968659 which is the patent with the latest expiry date in the FDA Orange Book. NNI is the original manufacturer of Victoza and did not acquire the product from a different company.
2020	Rx0000033	Novo	03/31/2020	00169413212	Ozempic (0.25 or 0.5 MG/DOSE) Subcutaneous Solution Pen-injector 2 MG/1.5ML	01/10/2020	38.62	811.05	06/21/2033	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	NNI holds a number of patents related to Ozempic and has included the expiration date for Patent #10335462 which is the patent with the latest expiry date in the FDA Orange Book. NNI is the original manufacturer of Ozempic and did not acquire the product from a different company.
2020	Rx0000033	Novo	03/31/2020	00169413602	Ozempic (1 MG/DOSE) Subcutaneous Solution Pen-injector 2 MG/1.5ML	01/10/2020	38.62	811.05	06/21/2033	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	NNI holds a number of patents related to Ozempic and has included the expiration date for Patent #10335462 which is the patent with the latest expiry date in the FDA Orange Book. NNI is the original manufacturer of Ozempic and did not acquire the product from a different company.
2020	Rx0000015	AstraZeneca	03/31/2020	00310620530	Farxiga 5mg Tablets 30 Count Bottle	01/01/2020	14.77	507.18	05/26/2030	Single Source Drug	590696676	None	"AstraZeneca makes decisions on price revisions annually based on market conditions, a common practice across the industry. These decisions are "AstraZeneca makes decisions on price revisions annually based on market conditions, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients. When making pricing decisions AstraZeneca takes the following actions: - We take into account not only the budget impact to payers but also consider patient out of pocket costs to ensure that our treatments reach the patients who need them. - We seek feedback from payers and providers through meetings, advisory boards, and third party research. - We price responsibly and in line with current treatment costs where treatment options exist. - We consider factors such as Annual CPI-U rates and increases in manufacturing and transportation costs. - We reinvest into R&D to identify future medicines to improve the lives of patients. "	None	AstraZeneca is a science-led biopharmaceutical business, and our innovative medicines are used by millions of patients worldwide. Patients and science are at the heart of everything we do, and we put careful consideration into determining the value and ultimately the cost of our medicines. Many factors go into these decisions such as the benefits our medicines provide and their potential to reduce healthcare spending on other costlier medical procedures. Equally important, these decisions enable us to invest in discovering and developing future innovative medicines where new treatments are needed.	None	02/01/2014	Bristol-Myers Squibb	2700000000	None	AstraZeneca paid Bristol-Myers Squibb $2.7 billion of initial consideration. AstraZeneca has also agreed to pay up to $1.4 billion in regulatory, launch and sales payments, and various sales-related royalty payments up until 2025, $600 million of which relates to the approval of Farxiga in the US. In addition, AstraZeneca may make payments of up to $225 million when certain assets are subsequently transferred.	289.20	289.20	2014	289.20	None	We note that § 96065, Wholesale Acquisition Cost Increase Notification, subparagraph (c), states as follows: “Total wholesale acquisition cost increase includes the current proposed wholesale acquisition cost increase and the sum of the wholesale acquisition cost increases that occurred in the current calendar year to date and the two previous calendar years.” AstraZeneca’s current proposed WAC increase is effective January 1, 2020. The price increases for the two previous calendar years were effective January 1, 2019 and January 1, 2018, respectively. We believe that the plain language of § 96065 (c) unambiguously supports our original reporting methodology. Nevertheless, in order to resolve this issue amicably, we are submitting this amended report.
2020	Rx0000015	AstraZeneca	03/31/2020	00310620530	Farxiga 5mg Tablets 30 Count Bottle	01/01/2020	14.77	507.18	05/26/2030	Single Source Drug	590696676	None	"AstraZeneca makes decisions on price revisions annually based on market conditions, a common practice across the industry. These decisions are "AstraZeneca makes decisions on price revisions annually based on market conditions, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients. When making pricing decisions AstraZeneca takes the following actions: - We take into account not only the budget impact to payers but also consider patient out of pocket costs to ensure that our treatments reach the patients who need them. - We seek feedback from payers and providers through meetings, advisory boards, and third party research. - We price responsibly and in line with current treatment costs where treatment options exist. - We consider factors such as Annual CPI-U rates and increases in manufacturing and transportation costs. - We reinvest into R&D to identify future medicines to improve the lives of patients. "	None	AstraZeneca is a science-led biopharmaceutical business, and our innovative medicines are used by millions of patients worldwide. Patients and science are at the heart of everything we do, and we put careful consideration into determining the value and ultimately the cost of our medicines. Many factors go into these decisions such as the benefits our medicines provide and their potential to reduce healthcare spending on other costlier medical procedures. Equally important, these decisions enable us to invest in discovering and developing future innovative medicines where new treatments are needed.	None	02/01/2014	Bristol-Myers Squibb	2700000000	None	AstraZeneca paid Bristol-Myers Squibb $2.7 billion of initial consideration. AstraZeneca has also agreed to pay up to $1.4 billion in regulatory, launch and sales payments, and various sales-related royalty payments up until 2025, $600 million of which relates to the approval of Farxiga in the US. In addition, AstraZeneca may make payments of up to $225 million when certain assets are subsequently transferred.	289.20	289.20	2014	289.20	None	We note that § 96065, Wholesale Acquisition Cost Increase Notification, subparagraph (c), states as follows: “Total wholesale acquisition cost increase includes the current proposed wholesale acquisition cost increase and the sum of the wholesale acquisition cost increases that occurred in the current calendar year to date and the two previous calendar years.” AstraZeneca’s current proposed WAC increase is effective January 1, 2020. The price increases for the two previous calendar years were effective January 1, 2019 and January 1, 2018, respectively. We believe that the plain language of § 96065 (c) unambiguously supports our original reporting methodology. Nevertheless, in order to resolve this issue amicably, we are submitting this amended report.
2020	Rx0000015	AstraZeneca	03/31/2020	00310621030	Farxiga 10mg Tablets 30 Count Bottle	01/01/2020	14.77	507.18	05/26/2030	Single Source Drug	1438170485	None	"AstraZeneca makes decisions on price revisions annually based on market conditions, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients. When making pricing decisions AstraZeneca takes the following actions: - We take into account not only the budget impact to payers but also consider patient out of pocket costs to ensure that our treatments reach the patients who need them. - We seek feedback from payers and providers through meetings, advisory boards, and third party research. - We price responsibly and in line with current treatment costs where treatment options exist. - We consider factors such as Annual CPI-U rates and increases in manufacturing and transportation costs. - We reinvest into R&D to identify future medicines to improve the lives of patients. "	None	AstraZeneca is a science-led biopharmaceutical business, and our innovative medicines are used by millions of patients worldwide. Patients and science are at the heart of everything we do, and we put careful consideration into determining the value and ultimately the cost of our medicines. Many factors go into these decisions such as the benefits our medicines provide and their potential to reduce healthcare spending on other costlier medical procedures. Equally important, these decisions enable us to invest in discovering and developing future innovative medicines where new treatments are needed.	None	02/01/2014	Bristol-Myers Squibb	2700000000	None	AstraZeneca paid Bristol-Myers Squibb $2.7 billion of initial consideration. AstraZeneca has also agreed to pay up to $1.4 billion in regulatory, launch and sales payments, and various sales-related royalty payments up until 2025, $600 million of which relates to the approval of Farxiga in the US. In addition, AstraZeneca may make payments of up to $225 million when certain assets are subsequently transferred.	289.20	289.20	2014	289.20	None	We note that § 96065, Wholesale Acquisition Cost Increase Notification, subparagraph (c), states as follows: “Total wholesale acquisition cost increase includes the current proposed wholesale acquisition cost increase and the sum of the wholesale acquisition cost increases that occurred in the current calendar year to date and the two previous calendar years.” AstraZeneca’s current proposed WAC increase is effective January 1, 2020. The price increases for the two previous calendar years were effective January 1, 2019 and January 1, 2018, respectively. We believe that the plain language of § 96065 (c) unambiguously supports our original reporting methodology. Nevertheless, in order to resolve this issue amicably, we are submitting this amended report.
2020	Rx0000015	AstraZeneca	03/31/2020	00310621030	Farxiga 10mg Tablets 30 Count Bottle	01/01/2020	14.77	507.18	05/26/2030	Single Source Drug	1438170485	None	"AstraZeneca makes decisions on price revisions annually based on market conditions, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients. When making pricing decisions AstraZeneca takes the following actions: - We take into account not only the budget impact to payers but also consider patient out of pocket costs to ensure that our treatments reach the patients who need them. - We seek feedback from payers and providers through meetings, advisory boards, and third party research. - We price responsibly and in line with current treatment costs where treatment options exist. - We consider factors such as Annual CPI-U rates and increases in manufacturing and transportation costs. - We reinvest into R&D to identify future medicines to improve the lives of patients. "	None	AstraZeneca is a science-led biopharmaceutical business, and our innovative medicines are used by millions of patients worldwide. Patients and science are at the heart of everything we do, and we put careful consideration into determining the value and ultimately the cost of our medicines. Many factors go into these decisions such as the benefits our medicines provide and their potential to reduce healthcare spending on other costlier medical procedures. Equally important, these decisions enable us to invest in discovering and developing future innovative medicines where new treatments are needed.	None	02/01/2014	Bristol-Myers Squibb	2700000000	None	AstraZeneca paid Bristol-Myers Squibb $2.7 billion of initial consideration. AstraZeneca has also agreed to pay up to $1.4 billion in regulatory, launch and sales payments, and various sales-related royalty payments up until 2025, $600 million of which relates to the approval of Farxiga in the US. In addition, AstraZeneca may make payments of up to $225 million when certain assets are subsequently transferred.	289.20	289.20	2014	289.20	None	We note that § 96065, Wholesale Acquisition Cost Increase Notification, subparagraph (c), states as follows: “Total wholesale acquisition cost increase includes the current proposed wholesale acquisition cost increase and the sum of the wholesale acquisition cost increases that occurred in the current calendar year to date and the two previous calendar years.” AstraZeneca’s current proposed WAC increase is effective January 1, 2020. The price increases for the two previous calendar years were effective January 1, 2019 and January 1, 2018, respectively. We believe that the plain language of § 96065 (c) unambiguously supports our original reporting methodology. Nevertheless, in order to resolve this issue amicably, we are submitting this amended report.
2020	Rx0000015	AstraZeneca	03/31/2020	00310625030	Xigduo XR 5-500mg Tablets 30 Count Bottle	01/01/2020	14.77	507.18	11/12/2030	Single Source Drug	23387060	None	"AstraZeneca makes decisions on price revisions annually based on market conditions, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients. When making pricing decisions AstraZeneca takes the following actions: - We take into account not only the budget impact to payers but also consider patient out of pocket costs to ensure that our treatments reach the patients who need them. - We seek feedback from payers and providers through meetings, advisory boards, and third party research. - We price responsibly and in line with current treatment costs where treatment options exist. - We consider factors such as Annual CPI-U rates and increases in manufacturing and transportation costs. - We reinvest into R&D to identify future medicines to improve the lives of patients. "	None	AstraZeneca is a science-led biopharmaceutical business, and our innovative medicines are used by millions of patients worldwide. Patients and science are at the heart of everything we do, and we put careful consideration into determining the value and ultimately the cost of our medicines. Many factors go into these decisions such as the benefits our medicines provide and their potential to reduce healthcare spending on other costlier medical procedures. Equally important, these decisions enable us to invest in discovering and developing future innovative medicines where new treatments are needed.	None	None	None	None	None	None	None	None	None	None	None	We note that § 96065, Wholesale Acquisition Cost Increase Notification, subparagraph (c), states as follows: “Total wholesale acquisition cost increase includes the current proposed wholesale acquisition cost increase and the sum of the wholesale acquisition cost increases that occurred in the current calendar year to date and the two previous calendar years.” AstraZeneca’s current proposed WAC increase is effective January 1, 2020. The price increases for the two previous calendar years were effective January 1, 2019 and January 1, 2018, respectively. We believe that the plain language of § 96065 (c) unambiguously supports our original reporting methodology. Nevertheless, in order to resolve this issue amicably, we are submitting this amended report.
2020	Rx0000015	AstraZeneca	03/31/2020	00310625030	Xigduo XR 5-500mg Tablets 30 Count Bottle	01/01/2020	14.77	507.18	11/12/2030	Single Source Drug	23387060	None	"AstraZeneca makes decisions on price revisions annually based on market conditions, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients. When making pricing decisions AstraZeneca takes the following actions: - We take into account not only the budget impact to payers but also consider patient out of pocket costs to ensure that our treatments reach the patients who need them. - We seek feedback from payers and providers through meetings, advisory boards, and third party research. - We price responsibly and in line with current treatment costs where treatment options exist. - We consider factors such as Annual CPI-U rates and increases in manufacturing and transportation costs. - We reinvest into R&D to identify future medicines to improve the lives of patients. "	None	AstraZeneca is a science-led biopharmaceutical business, and our innovative medicines are used by millions of patients worldwide. Patients and science are at the heart of everything we do, and we put careful consideration into determining the value and ultimately the cost of our medicines. Many factors go into these decisions such as the benefits our medicines provide and their potential to reduce healthcare spending on other costlier medical procedures. Equally important, these decisions enable us to invest in discovering and developing future innovative medicines where new treatments are needed.	None	None	None	None	None	None	None	None	None	None	None	We note that § 96065, Wholesale Acquisition Cost Increase Notification, subparagraph (c), states as follows: “Total wholesale acquisition cost increase includes the current proposed wholesale acquisition cost increase and the sum of the wholesale acquisition cost increases that occurred in the current calendar year to date and the two previous calendar years.” AstraZeneca’s current proposed WAC increase is effective January 1, 2020. The price increases for the two previous calendar years were effective January 1, 2019 and January 1, 2018, respectively. We believe that the plain language of § 96065 (c) unambiguously supports our original reporting methodology. Nevertheless, in order to resolve this issue amicably, we are submitting this amended report.
2020	Rx0000015	AstraZeneca	03/31/2020	00310626060	Xigduo XR 5-1000mg Tablets 60 Count Bottle	01/01/2020	14.77	507.18	11/12/2030	Single Source Drug	237728896	None	"AstraZeneca makes decisions on price revisions annually based on market conditions, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients. When making pricing decisions AstraZeneca takes the following actions: - We take into account not only the budget impact to payers but also consider patient out of pocket costs to ensure that our treatments reach the patients who need them. - We seek feedback from payers and providers through meetings, advisory boards, and third party research. - We price responsibly and in line with current treatment costs where treatment options exist. - We consider factors such as Annual CPI-U rates and increases in manufacturing and transportation costs. - We reinvest into R&D to identify future medicines to improve the lives of patients. "	None	AstraZeneca is a science-led biopharmaceutical business, and our innovative medicines are used by millions of patients worldwide. Patients and science are at the heart of everything we do, and we put careful consideration into determining the value and ultimately the cost of our medicines. Many factors go into these decisions such as the benefits our medicines provide and their potential to reduce healthcare spending on other costlier medical procedures. Equally important, these decisions enable us to invest in discovering and developing future innovative medicines where new treatments are needed.	None	None	None	None	None	None	None	None	None	None	None	We note that § 96065, Wholesale Acquisition Cost Increase Notification, subparagraph (c), states as follows: “Total wholesale acquisition cost increase includes the current proposed wholesale acquisition cost increase and the sum of the wholesale acquisition cost increases that occurred in the current calendar year to date and the two previous calendar years.” AstraZeneca’s current proposed WAC increase is effective January 1, 2020. The price increases for the two previous calendar years were effective January 1, 2019 and January 1, 2018, respectively. We believe that the plain language of § 96065 (c) unambiguously supports our original reporting methodology. Nevertheless, in order to resolve this issue amicably, we are submitting this amended report.
2020	Rx0000015	AstraZeneca	03/31/2020	00310626060	Xigduo XR 5-1000mg Tablets 60 Count Bottle	01/01/2020	14.77	507.18	11/12/2030	Single Source Drug	237728896	None	"AstraZeneca makes decisions on price revisions annually based on market conditions, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients. When making pricing decisions AstraZeneca takes the following actions: - We take into account not only the budget impact to payers but also consider patient out of pocket costs to ensure that our treatments reach the patients who need them. - We seek feedback from payers and providers through meetings, advisory boards, and third party research. - We price responsibly and in line with current treatment costs where treatment options exist. - We consider factors such as Annual CPI-U rates and increases in manufacturing and transportation costs. - We reinvest into R&D to identify future medicines to improve the lives of patients. "	None	AstraZeneca is a science-led biopharmaceutical business, and our innovative medicines are used by millions of patients worldwide. Patients and science are at the heart of everything we do, and we put careful consideration into determining the value and ultimately the cost of our medicines. Many factors go into these decisions such as the benefits our medicines provide and their potential to reduce healthcare spending on other costlier medical procedures. Equally important, these decisions enable us to invest in discovering and developing future innovative medicines where new treatments are needed.	None	None	None	None	None	None	None	None	None	None	None	We note that § 96065, Wholesale Acquisition Cost Increase Notification, subparagraph (c), states as follows: “Total wholesale acquisition cost increase includes the current proposed wholesale acquisition cost increase and the sum of the wholesale acquisition cost increases that occurred in the current calendar year to date and the two previous calendar years.” AstraZeneca’s current proposed WAC increase is effective January 1, 2020. The price increases for the two previous calendar years were effective January 1, 2019 and January 1, 2018, respectively. We believe that the plain language of § 96065 (c) unambiguously supports our original reporting methodology. Nevertheless, in order to resolve this issue amicably, we are submitting this amended report.
2020	Rx0000015	AstraZeneca	03/31/2020	00310627030	Xigduo XR 10-500mg Tablets 30 Count Bottle	01/01/2020	14.77	507.18	11/12/2030	Single Source Drug	13548819	None	"AstraZeneca makes decisions on price revisions annually based on market conditions, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients. When making pricing decisions AstraZeneca takes the following actions: - We take into account not only the budget impact to payers but also consider patient out of pocket costs to ensure that our treatments reach the patients who need them. - We seek feedback from payers and providers through meetings, advisory boards, and third party research. - We price responsibly and in line with current treatment costs where treatment options exist. - We consider factors such as Annual CPI-U rates and increases in manufacturing and transportation costs. - We reinvest into R&D to identify future medicines to improve the lives of patients. "	None	AstraZeneca is a science-led biopharmaceutical business, and our innovative medicines are used by millions of patients worldwide. Patients and science are at the heart of everything we do, and we put careful consideration into determining the value and ultimately the cost of our medicines. Many factors go into these decisions such as the benefits our medicines provide and their potential to reduce healthcare spending on other costlier medical procedures. Equally important, these decisions enable us to invest in discovering and developing future innovative medicines where new treatments are needed.	None	None	None	None	None	None	None	None	None	None	None	We note that § 96065, Wholesale Acquisition Cost Increase Notification, subparagraph (c), states as follows: “Total wholesale acquisition cost increase includes the current proposed wholesale acquisition cost increase and the sum of the wholesale acquisition cost increases that occurred in the current calendar year to date and the two previous calendar years.” AstraZeneca’s current proposed WAC increase is effective January 1, 2020. The price increases for the two previous calendar years were effective January 1, 2019 and January 1, 2018, respectively. We believe that the plain language of § 96065 (c) unambiguously supports our original reporting methodology. Nevertheless, in order to resolve this issue amicably, we are submitting this amended report.
2020	Rx0000015	AstraZeneca	03/31/2020	00310627030	Xigduo XR 10-500mg Tablets 30 Count Bottle	01/01/2020	14.77	507.18	11/12/2030	Single Source Drug	13548819	None	"AstraZeneca makes decisions on price revisions annually based on market conditions, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients. When making pricing decisions AstraZeneca takes the following actions: - We take into account not only the budget impact to payers but also consider patient out of pocket costs to ensure that our treatments reach the patients who need them. - We seek feedback from payers and providers through meetings, advisory boards, and third party research. - We price responsibly and in line with current treatment costs where treatment options exist. - We consider factors such as Annual CPI-U rates and increases in manufacturing and transportation costs. - We reinvest into R&D to identify future medicines to improve the lives of patients. "	None	AstraZeneca is a science-led biopharmaceutical business, and our innovative medicines are used by millions of patients worldwide. Patients and science are at the heart of everything we do, and we put careful consideration into determining the value and ultimately the cost of our medicines. Many factors go into these decisions such as the benefits our medicines provide and their potential to reduce healthcare spending on other costlier medical procedures. Equally important, these decisions enable us to invest in discovering and developing future innovative medicines where new treatments are needed.	None	None	None	None	None	None	None	None	None	None	None	We note that § 96065, Wholesale Acquisition Cost Increase Notification, subparagraph (c), states as follows: “Total wholesale acquisition cost increase includes the current proposed wholesale acquisition cost increase and the sum of the wholesale acquisition cost increases that occurred in the current calendar year to date and the two previous calendar years.” AstraZeneca’s current proposed WAC increase is effective January 1, 2020. The price increases for the two previous calendar years were effective January 1, 2019 and January 1, 2018, respectively. We believe that the plain language of § 96065 (c) unambiguously supports our original reporting methodology. Nevertheless, in order to resolve this issue amicably, we are submitting this amended report.
2020	Rx0000015	AstraZeneca	03/31/2020	00310628030	Xigduo XR 10-1000mg Tablets 30 Count Bottle	01/01/2020	14.77	507.18	11/12/2030	Single Source Drug	128234044	None	"AstraZeneca makes decisions on price revisions annually based on market conditions, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients. When making pricing decisions AstraZeneca takes the following actions: - We take into account not only the budget impact to payers but also consider patient out of pocket costs to ensure that our treatments reach the patients who need them. - We seek feedback from payers and providers through meetings, advisory boards, and third party research. - We price responsibly and in line with current treatment costs where treatment options exist. - We consider factors such as Annual CPI-U rates and increases in manufacturing and transportation costs. - We reinvest into R&D to identify future medicines to improve the lives of patients. "	None	AstraZeneca is a science-led biopharmaceutical business, and our innovative medicines are used by millions of patients worldwide. Patients and science are at the heart of everything we do, and we put careful consideration into determining the value and ultimately the cost of our medicines. Many factors go into these decisions such as the benefits our medicines provide and their potential to reduce healthcare spending on other costlier medical procedures. Equally important, these decisions enable us to invest in discovering and developing future innovative medicines where new treatments are needed.	None	None	None	None	None	None	None	None	None	None	None	We note that § 96065, Wholesale Acquisition Cost Increase Notification, subparagraph (c), states as follows: “Total wholesale acquisition cost increase includes the current proposed wholesale acquisition cost increase and the sum of the wholesale acquisition cost increases that occurred in the current calendar year to date and the two previous calendar years.” AstraZeneca’s current proposed WAC increase is effective January 1, 2020. The price increases for the two previous calendar years were effective January 1, 2019 and January 1, 2018, respectively. We believe that the plain language of § 96065 (c) unambiguously supports our original reporting methodology. Nevertheless, in order to resolve this issue amicably, we are submitting this amended report.
2020	Rx0000015	AstraZeneca	03/31/2020	00310628030	Xigduo XR 10-1000mg Tablets 30 Count Bottle	01/01/2020	14.77	507.18	11/12/2030	Single Source Drug	128234044	None	"AstraZeneca makes decisions on price revisions annually based on market conditions, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients. When making pricing decisions AstraZeneca takes the following actions: - We take into account not only the budget impact to payers but also consider patient out of pocket costs to ensure that our treatments reach the patients who need them. - We seek feedback from payers and providers through meetings, advisory boards, and third party research. - We price responsibly and in line with current treatment costs where treatment options exist. - We consider factors such as Annual CPI-U rates and increases in manufacturing and transportation costs. - We reinvest into R&D to identify future medicines to improve the lives of patients. "	None	AstraZeneca is a science-led biopharmaceutical business, and our innovative medicines are used by millions of patients worldwide. Patients and science are at the heart of everything we do, and we put careful consideration into determining the value and ultimately the cost of our medicines. Many factors go into these decisions such as the benefits our medicines provide and their potential to reduce healthcare spending on other costlier medical procedures. Equally important, these decisions enable us to invest in discovering and developing future innovative medicines where new treatments are needed.	None	None	None	None	None	None	None	None	None	None	None	We note that § 96065, Wholesale Acquisition Cost Increase Notification, subparagraph (c), states as follows: “Total wholesale acquisition cost increase includes the current proposed wholesale acquisition cost increase and the sum of the wholesale acquisition cost increases that occurred in the current calendar year to date and the two previous calendar years.” AstraZeneca’s current proposed WAC increase is effective January 1, 2020. The price increases for the two previous calendar years were effective January 1, 2019 and January 1, 2018, respectively. We believe that the plain language of § 96065 (c) unambiguously supports our original reporting methodology. Nevertheless, in order to resolve this issue amicably, we are submitting this amended report.
2020	Rx0000015	AstraZeneca	09/30/2020	00310653004	Bydureon 2mg Pen 4 Syringes	07/01/2020	14.42	735.18	03/21/2028	Single Source Drug	815082319	None	AstraZeneca makes decisions on price revisions annually based on market conditions, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients. When making pricing decisions AstraZeneca takes the following actions: - We take into account not only the budget impact to payers but also consider patient out of pocket costs to ensure that our treatments reach the patients who need them. - We seek feedback from payers and providers through meetings, advisory boards, and third party research. - We price responsibly and in line with current treatment costs where treatment options exist. - We consider factors such as Annual CPI-U rates and increases in manufacturing and transportation costs. - We reinvest into R&D to identify future medicines to improve the lives of patients.	None	AstraZeneca is a science-led biopharmaceutical business, and our innovative medicines are used by millions of patients worldwide. Patients and science are at the heart of everything we do, and we put careful consideration into determining the value and ultimately the cost of our medicines. Many factors go into these decisions such as the benefits our medicines provide and their potential to reduce healthcare spending on other costlier medical procedures. Equally important, these decisions enable us to invest in discovering and developing future innovative medicines where new treatments are needed.	None	02/01/2014	Bristol-Myers Squibb	2700000000	None	AstraZeneca paid Bristol-Myers Squibb $2.7 billion of initial consideration for acquisition of the company's diabetes alliance. AstraZeneca has also agreed to pay up to $1.4 billion in regulatory, launch and sales payments, and various sales-related royalty payments up until 2025. In addition, AstraZeneca may make payments of up to $225 million when certain assets are subsequently transferred.	407.45	None	2012	323.44	None	None
2020	Rx0000015	AstraZeneca	09/30/2020	00310654004	Bydureon 2mg Autoinjector 4 Syringes	07/01/2020	14.42	735.18	10/04/2030	Single Source Drug	668761831	None	AstraZeneca makes decisions on price revisions annually based on market conditions, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients. When making pricing decisions AstraZeneca takes the following actions: - We take into account not only the budget impact to payers but also consider patient out of pocket costs to ensure that our treatments reach the patients who need them. - We seek feedback from payers and providers through meetings, advisory boards, and third party research. - We price responsibly and in line with current treatment costs where treatment options exist. - We consider factors such as Annual CPI-U rates and increases in manufacturing and transportation costs. - We reinvest into R&D to identify future medicines to improve the lives of patients.	None	AstraZeneca is a science-led biopharmaceutical business, and our innovative medicines are used by millions of patients worldwide. Patients and science are at the heart of everything we do, and we put careful consideration into determining the value and ultimately the cost of our medicines. Many factors go into these decisions such as the benefits our medicines provide and their potential to reduce healthcare spending on other costlier medical procedures. Equally important, these decisions enable us to invest in discovering and developing future innovative medicines where new treatments are needed.	None	02/01/2014	Bristol-Myers Squibb	2700000000	None	AstraZeneca paid Bristol-Myers Squibb $2.7 billion of initial consideration for acquisition of the company's diabetes alliance. AstraZeneca has also agreed to pay up to $1.4 billion in regulatory, launch and sales payments, and various sales-related royalty payments up until 2025. In addition, AstraZeneca may make payments of up to $225 million when certain assets are subsequently transferred.	407.45	None	2012	323.44	None	None
2020	Rx0000015	AstraZeneca	03/31/2020	00310678030	Qtern 5mg-10mg Tablets 30 Count Bottle	01/01/2020	14.77	507.18	12/16/2029	Single Source Drug	10919684	None	"AstraZeneca makes decisions on price revisions annually based on market conditions, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients. When making pricing decisions AstraZeneca takes the following actions: - We take into account not only the budget impact to payers but also consider patient out of pocket costs to ensure that our treatments reach the patients who need them. - We seek feedback from payers and providers through meetings, advisory boards, and third party research. - We price responsibly and in line with current treatment costs where treatment options exist. - We consider factors such as Annual CPI-U rates and increases in manufacturing and transportation costs. - We reinvest into R&D to identify future medicines to improve the lives of patients. "	None	AstraZeneca is a science-led biopharmaceutical business, and our innovative medicines are used by millions of patients worldwide. Patients and science are at the heart of everything we do, and we put careful consideration into determining the value and ultimately the cost of our medicines. Many factors go into these decisions such as the benefits our medicines provide and their potential to reduce healthcare spending on other costlier medical procedures. Equally important, these decisions enable us to invest in discovering and developing future innovative medicines where new treatments are needed.	None	None	None	None	None	None	None	None	None	None	None	We note that § 96065, Wholesale Acquisition Cost Increase Notification, subparagraph (c), states as follows: “Total wholesale acquisition cost increase includes the current proposed wholesale acquisition cost increase and the sum of the wholesale acquisition cost increases that occurred in the current calendar year to date and the two previous calendar years.” AstraZeneca’s current proposed WAC increase is effective January 1, 2020. The price increases for the two previous calendar years were effective January 1, 2019 and January 1, 2018, respectively. We believe that the plain language of § 96065 (c) unambiguously supports our original reporting methodology. Nevertheless, in order to resolve this issue amicably, we are submitting this amended report.
2020	Rx0000015	AstraZeneca	03/31/2020	00310678030	Qtern 5mg-10mg Tablets 30 Count Bottle	01/01/2020	14.77	507.18	12/16/2029	Single Source Drug	10919684	None	"AstraZeneca makes decisions on price revisions annually based on market conditions, a common practice across the industry. These decisions are designed to help us invest in bringing new medicines to market to address unmet patient needs and improve the lives of patients. When making pricing decisions AstraZeneca takes the following actions: - We take into account not only the budget impact to payers but also consider patient out of pocket costs to ensure that our treatments reach the patients who need them. - We seek feedback from payers and providers through meetings, advisory boards, and third party research. - We price responsibly and in line with current treatment costs where treatment options exist. - We consider factors such as Annual CPI-U rates and increases in manufacturing and transportation costs. - We reinvest into R&D to identify future medicines to improve the lives of patients. "	None	AstraZeneca is a science-led biopharmaceutical business, and our innovative medicines are used by millions of patients worldwide. Patients and science are at the heart of everything we do, and we put careful consideration into determining the value and ultimately the cost of our medicines. Many factors go into these decisions such as the benefits our medicines provide and their potential to reduce healthcare spending on other costlier medical procedures. Equally important, these decisions enable us to invest in discovering and developing future innovative medicines where new treatments are needed.	None	None	None	None	None	None	None	None	None	None	None	We note that § 96065, Wholesale Acquisition Cost Increase Notification, subparagraph (c), states as follows: “Total wholesale acquisition cost increase includes the current proposed wholesale acquisition cost increase and the sum of the wholesale acquisition cost increases that occurred in the current calendar year to date and the two previous calendar years.” AstraZeneca’s current proposed WAC increase is effective January 1, 2020. The price increases for the two previous calendar years were effective January 1, 2019 and January 1, 2018, respectively. We believe that the plain language of § 96065 (c) unambiguously supports our original reporting methodology. Nevertheless, in order to resolve this issue amicably, we are submitting this amended report.
2020	Rx0000038	Boehringer Ingelheim	03/31/2020	00597014030	TRADJENTA 5 MG TABLET 30	01/01/2020	26.17	462.34	03/05/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=369	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2020	Rx0000038	Boehringer Ingelheim	03/31/2020	00597014061	TRADJENTA 5 MG TABLET 100	01/01/2020	87.23	1541.13	03/05/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=370	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2020	Rx0000038	Boehringer Ingelheim	03/31/2020	00597014090	TRADJENTA 5 MG TABLET 90	01/01/2020	78.51	1387.02	03/05/2031	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=371	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2020	Rx0000038	Boehringer Ingelheim	03/31/2020	00597014618	JENTADUETO 2.5 MG-500 MG 180	01/01/2020	78.51	1387.02	06/04/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=373	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2020	Rx0000038	Boehringer Ingelheim	03/31/2020	00597014660	JENTADUETO 2.5 MG-500 MG 60	01/01/2020	26.17	462.34	06/04/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=374	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2020	Rx0000038	Boehringer Ingelheim	03/31/2020	00597014718	JENTADUETO 2.5 MG-850 MG 180	01/01/2020	78.51	1387.02	06/04/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=375	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2020	Rx0000038	Boehringer Ingelheim	03/31/2020	00597014760	JENTADUETO 2.5 MG-850 MG 60	01/01/2020	26.17	462.34	06/04/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=376	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2020	Rx0000038	Boehringer Ingelheim	03/31/2020	00597014818	JENTADUETO 2.5 MG-1,000 MG 180	01/01/2020	78.51	1387.02	06/04/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=377	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2020	Rx0000038	Boehringer Ingelheim	03/31/2020	00597014860	JENTADUETO 2.5 MG-1,000 MG 60	01/01/2020	26.17	462.34	06/04/2030	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=378	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2020	Rx0000038	Boehringer Ingelheim	03/31/2020	00597015230	JARDIANCE 10 MG TABLET 30	01/01/2020	29.57	522.42	06/11/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=379	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2020	Rx0000038	Boehringer Ingelheim	03/31/2020	00597015237	JARDIANCE 10 MG 30 TABLET	01/01/2020	29.57	522.42	06/11/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=380	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2020	Rx0000038	Boehringer Ingelheim	03/31/2020	00597015290	JARDIANCE 10 MG TABLET 90	01/01/2020	88.71	1567.25	06/11/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=381	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2020	Rx0000038	Boehringer Ingelheim	03/31/2020	00597015330	JARDIANCE 25 MG TABLET 30	01/01/2020	29.57	522.42	06/11/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=382	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2020	Rx0000038	Boehringer Ingelheim	03/31/2020	00597015337	JARDIANCE 25 MG 30 TABLET	01/01/2020	29.57	522.42	06/11/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=383	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2020	Rx0000038	Boehringer Ingelheim	03/31/2020	00597015390	JARDIANCE 25 MG TABLET 90	01/01/2020	88.71	1567.25	06/11/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=384	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2020	Rx0000038	Boehringer Ingelheim	03/31/2020	00597015918	SYNJARDY 5-500 MG TABLET 180	01/01/2020	88.71	1567.25	04/03/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=386	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2020	Rx0000038	Boehringer Ingelheim	03/31/2020	00597015960	SYNJARDY 5-500 MG TABLET 60	01/01/2020	29.57	522.42	04/03/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=387	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2020	Rx0000038	Boehringer Ingelheim	03/31/2020	00597016818	SYNJARDY 12.5-1,000 MG 180	01/01/2020	88.71	1567.25	04/03/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=389	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2020	Rx0000038	Boehringer Ingelheim	03/31/2020	00597016860	SYNJARDY 12.5-1,000 MG 60	01/01/2020	29.57	522.42	04/03/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=390	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2020	Rx0000038	Boehringer Ingelheim	03/31/2020	00597017518	SYNJARDY 5-1,000 MG 180	01/01/2020	88.71	1567.25	04/03/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=391	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2020	Rx0000038	Boehringer Ingelheim	03/31/2020	00597017560	SYNJARDY 5-1,000 MG 60	01/01/2020	29.57	522.42	04/03/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=392	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2020	Rx0000038	Boehringer Ingelheim	03/31/2020	00597018018	SYNJARDY 12.5-500 MG 180	01/01/2020	88.71	1567.25	04/03/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=393	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2020	Rx0000038	Boehringer Ingelheim	03/31/2020	00597018060	SYNJARDY 12.5-500 MG 60	01/01/2020	29.57	522.42	04/03/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=394	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2020	Rx0000038	Boehringer Ingelheim	03/31/2020	00597027073	JENTADUETO XR 2.5 MG-1,000 MG 60	01/01/2020	26.17	462.34	03/06/2033	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=396	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2020	Rx0000038	Boehringer Ingelheim	03/31/2020	00597027094	JENTADUETO XR 2.5 MG-1,000 MG 180	01/01/2020	78.51	1387.02	03/06/2033	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=397	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2020	Rx0000038	Boehringer Ingelheim	03/31/2020	00597027533	JENTADUETO XR 5 MG-1,000 MG TB 30	01/01/2020	26.17	462.34	03/06/2033	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=398	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2020	Rx0000038	Boehringer Ingelheim	03/31/2020	00597027581	JENTADUETO XR 5 MG-1,000 MG TB 90	01/01/2020	78.51	1387.02	03/06/2033	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=399	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2020	Rx0000038	Boehringer Ingelheim	03/31/2020	00597028073	SYNJARDY XR 10 mg-1,000 mg 30	01/01/2020	29.57	522.42	06/11/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=400	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2020	Rx0000038	Boehringer Ingelheim	03/31/2020	00597028090	SYNJARDY XR 10 mg-1,000 mg 90	01/01/2020	88.71	1567.25	06/11/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=401	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2020	Rx0000038	Boehringer Ingelheim	03/31/2020	00597029059	SYNJARDY XR 5 mg-1,000 mg 180	01/01/2020	88.71	1567.25	06/11/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=406	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2020	Rx0000038	Boehringer Ingelheim	03/31/2020	00597029074	SYNJARDY XR 5 mg-1,000 mg 60	01/01/2020	29.57	522.42	06/11/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=407	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2020	Rx0000038	Boehringer Ingelheim	03/31/2020	00597029578	SYNJARDY XR 25 mg-1,000 mg 90	01/01/2020	88.71	1567.25	06/11/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=408	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2020	Rx0000038	Boehringer Ingelheim	03/31/2020	00597029588	SYNJARDY XR 25 mg-1,000 mg 30	01/01/2020	29.57	522.42	06/11/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=409	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2020	Rx0000038	Boehringer Ingelheim	03/31/2020	00597030045	SYNJARDY XR 12.5 mg-1,000 mg 60	01/01/2020	29.57	522.42	06/11/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=410	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2020	Rx0000038	Boehringer Ingelheim	03/31/2020	00597030093	SYNJARDY XR 12.5 mg-1,000 mg 180	01/01/2020	88.71	1567.25	06/11/2034	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	https://reports.siera.oshpd.ca.gov/api/report/drug-pricing/attachment?id=411	For Column F as reflected in the FDA publication, Approved Drug Products with Therapeutic Equivalence Evaluations (the “Orange Book”), the latest patent expiration is provided. Not acquired within the last five years.
2020	Rx0000016	Janssen	03/31/2020	50458014030	INVOKANA® Strength:100mg Package Size:30 Form:Tablet	01/20/2020	24.22	518.53	02/26/2029	Single Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2020.
2020	Rx0000016	Janssen	03/31/2020	50458014090	INVOKANA® Strength:100mg Package Size:90 Form:Tablet	01/20/2020	72.67	1555.61	02/26/2029	Single Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2020.
2020	Rx0000016	Janssen	03/31/2020	50458014130	INVOKANA® Strength:300mg Package Size:30 Form:Tablet	01/20/2020	24.22	518.53	02/26/2029	Single Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2020.
2020	Rx0000016	Janssen	03/31/2020	50458014190	INVOKANA® Strength:300mg Package Size:90 Form:Tablet	01/20/2020	72.67	1555.61	02/26/2029	Single Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2020.
2020	Rx0000016	Janssen	03/31/2020	50458054060	INVOKAMET® Strength:50/500 MG Package Size:60 Form:Tablet	01/20/2020	24.22	518.54	02/26/2029	Single Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2020.
2020	Rx0000016	Janssen	03/31/2020	50458054160	INVOKAMET® Strength:50/1000 MG Package Size:60 Form:Tablet	01/20/2020	24.22	518.54	02/26/2029	Single Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2020.
2020	Rx0000016	Janssen	03/31/2020	50458054260	INVOKAMET® Strength:150/500 MG Package Size:60 Form:Tablet	01/20/2020	24.22	518.54	02/26/2029	Single Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2020.
2020	Rx0000016	Janssen	03/31/2020	50458054360	INVOKAMET® Strength:150/1000 MG Package Size:60 Form:Tablet	01/20/2020	24.22	518.54	02/26/2029	Single Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2020.
2020	Rx0000016	Janssen	03/31/2020	50458094001	INVOKAMET® XR Strength:50/500 MG Package Size:60 Form:Tablet	01/20/2020	24.22	518.54	02/26/2029	Single Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2020.
2020	Rx0000016	Janssen	03/31/2020	50458094101	INVOKAMET® XR Strength:50/1000 MG Package Size:60 Form:Tablet	01/20/2020	24.22	518.54	02/26/2029	Single Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2020.
2020	Rx0000016	Janssen	03/31/2020	50458094201	INVOKAMET® XR Strength:150/500 MG Package Size:60 Form:Tablet	01/20/2020	24.22	518.54	02/26/2029	Single Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2020.
2020	Rx0000016	Janssen	03/31/2020	50458094301	INVOKAMET® XR Strength:150/1000 MG Package Size:60 Form:Tablet	01/20/2020	24.22	518.54	02/26/2029	Single Source Drug	None	1	Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D.	None	Not Applicable	None	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2020.
2020	Rx0000092	Santarus, Inc.	03/31/2020	68012025820	CYCLOSET (bromocriptine mesytate tablets) 0.8 mg tablets, 200 ct	01/09/2020	50.32	889.06	04/30/2032	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	The product was not acquired within the last 5 years.